These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 26377741)

  • 1. New paradigms in hepatitis B management: only diamonds are forever.
    Coffin CS; Lee SS
    Br Med Bull; 2015; 116():79-91. PubMed ID: 26377741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B].
    Lu FM; Wang J; Chen XM; Jiang JN; Zhang WH; Zhao JM; Ren H; Hou JL; Xia NS
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):105-110. PubMed ID: 28297795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus: new therapeutic perspectives.
    Lin CL; Yang HC; Kao JH
    Liver Int; 2016 Jan; 36 Suppl 1():85-92. PubMed ID: 26725903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.
    Wu D; Ning Q
    J Infect Dis; 2017 Nov; 216(suppl_8):S771-S777. PubMed ID: 29156046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on hepatitis B virus infection.
    You CR; Lee SW; Jang JW; Yoon SK
    World J Gastroenterol; 2014 Oct; 20(37):13293-305. PubMed ID: 25309066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
    Wong GLH; Gane E; Lok ASF
    J Hepatol; 2022 Jun; 76(6):1249-1262. PubMed ID: 35589248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: novel therapies for hepatitis B virus cure - advances and perspectives.
    Lin CL; Kao JH
    Aliment Pharmacol Ther; 2016 Aug; 44(3):213-22. PubMed ID: 27302653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy.
    Zhao Q; Liu H; Tang L; Wang F; Tolufashe G; Chang J; Guo JT
    Antiviral Res; 2024 Jan; 221():105782. PubMed ID: 38110058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
    Kao JH
    Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
    Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
    J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can we cure hepatitis B virus with novel direct-acting antivirals?
    Martinez MG; Villeret F; Testoni B; Zoulim F
    Liver Int; 2020 Feb; 40 Suppl 1():27-34. PubMed ID: 32077597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of viral transcripts as a concept for future HBV therapies.
    Seeger C
    Curr Opin Virol; 2018 Jun; 30():18-23. PubMed ID: 29453098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA.
    Wong DK; Seto WK; Cheung KS; Chong CK; Huang FY; Fung J; Lai CL; Yuen MF
    Liver Int; 2017 Jul; 37(7):995-1001. PubMed ID: 27992681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
    Alonso S; Guerra AR; Carreira L; Ferrer JÁ; Gutiérrez ML; Fernandez-Rodriguez CM
    BMC Gastroenterol; 2017 Dec; 17(1):168. PubMed ID: 29268704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance.
    Yang HC; Kao JH
    Emerg Microbes Infect; 2014 Sep; 3(9):e64. PubMed ID: 26038757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aiming for cure in HBV and HDV infection.
    Petersen J; Thompson AJ; Levrero M
    J Hepatol; 2016 Oct; 65(4):835-848. PubMed ID: 27270043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.
    Li J; Sun X; Fang J; Wang C; Han G; Ren W
    Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):635-643. PubMed ID: 28438570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.